Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Conferences

Conference Coverage

Conference Listing

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

Articles

In a recent webinar, experts explored the Most Favored Nation mandate’s implications on drug pricing, patient access, and pharmaceutical innovation.

Unpacking the Complexity of the Most Favored Nation Mandate

Kimberly Rath, PharmD, is a freelance health writer who previously worked as a clinical pharmacist with Elevance Health for a decade. She has also worked for Amerigroup and Sentara Group.

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis. 

Refined iRR6 Model Improves Risk Stratification in Intermediate-1 Myelofibrosis 

Findings reveal that alternative polyadenylation regulates SASP factors and may fuel age-related pulmonary fibrosis. 

Senescent Fibroblasts in IPF Linked to NUDT21 Deficiency

Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (

®). She joined AJMC® in 2013 and is the primary staff editor for 

the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for 

®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for 

Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on 

Zanubrutinib shows superior progression-free and overall survival in relapsed mantle cell lymphoma compared with acalabrutinib, according to a new analysis.

Indirect Comparison Finds Zanubrutinib Associated With Better PFS, OS Than Acalabrutinib in MCL

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1.125rem

Nicolas Girard, MD, PhD, is head of the medical oncology department at Institut Curie in France.

The subcutaneous dose had comparable efficacy to intravenous dosing while enhancing patient convenience in non–small cell lung cancer, explains Nicolas Girard, MD, PhD.

SubQ Amivantamab Q4W Maintains Efficacy, Improves Convenience: Nicolas Girard, MD, PhD